These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33486641)

  • 41. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
    Schlam I; Dower J; Lynce F
    Curr Oncol Rep; 2024 Apr; 26(4):336-345. PubMed ID: 38393609
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
    Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
    Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
    J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
    Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
    Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients.
    Livingston-Rosanoff D; Hanlon B; Marka N; Vande Walle K; Stankowski-Drengler T; Schumacher J; Greenberg CC; Neuman H; Wilke LG
    Breast J; 2020 Apr; 26(4):625-629. PubMed ID: 31513322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant treatment of breast cancer--Clinical and research perspective.
    Loibl S; Denkert C; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S73-7. PubMed ID: 26387601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Takahashi Y; Iwamoto T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kawada K; Kochi M; Ikeda H; Shien T; Taira N; Matsuoka J; Doihara H; Toyooka S
    Clin Breast Cancer; 2020 Apr; 20(2):117-124.e4. PubMed ID: 31570267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
    Grova MM; Strassle PD; Navajas EE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
    Ann Surg Oncol; 2021 Apr; 28(4):2182-2190. PubMed ID: 32974693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
    Gonzalez-Ericsson PI; Wulfkhule JD; Gallagher RI; Sun X; Axelrod ML; Sheng Q; Luo N; Gomez H; Sanchez V; Sanders M; Pusztai L; Petricoin E; Blenman KRM; Balko JM;
    Clin Cancer Res; 2021 Oct; 27(19):5299-5306. PubMed ID: 34315723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
    Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
    Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
    Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.
    Miglietta F; Dieci MV; Griguolo G; Guarneri V
    Cancer Treat Rev; 2021 Jul; 98():102222. PubMed ID: 34023642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.